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Neutrophil attractanVactivation protein-i (NAP-i) has sequence similarity to platelet
factor-4 (PF-4) and to NAP-2 (a truncated form of connective tissue activating protein-Ill
[CTAP-lII(des 1-15)]. We compared chemotactic activity for neutrophils of these related
proteins. We also included for comparison CTAP-III, CTAP-lll(des 1-13), the C-terminal
dodecapeptide of PF-4 [PF-4(59-70)J, and C5a. Chemotactic potency (EC) was highest
for NAP-i and C5a. Although chemotactic efficacy (peak percentage of neutrophils
migrating) was comparable for C5a, NAP-i , and NAP-2, the NAP-2 response occurred only
at concentrations 100-fold higher than the NAP-i EC of i08 M. Data for the CTAP-IIl
proteins confirmed that CTAP-III is not an attractant and that chemotactic activity appears
as a result of cleavage of residues at the N-terminus to make CTAP-III(des 1-13) or NAP-2
[CTAP-IlI(des 1-i 5)]. Chemotactic activity of PF-4 was low and variable, with no significant
response by neutrophils from six of nine subjects. In contrast, PF-4(59-70) regularly
induced high chemotactic responses, although the EC50 of 1.6 x i0 M was 1,000-fold
greater than that of NAP-i . The binding of fluoresceinated NAP-i to neutrophils was
inhibited by unlabeled NAP-i or NAP-2 but not by PF-4 or PF-4 (59-70). This suggests that
NAP-2 interacts with the neutrophil NAP-i receptor. Despite the low chemotactic potency
of NAP-2, it is a potential attractant at sites of injury because of the relatively large
amounts of the parent CTAP-IIl released from platelets, as indicated by a serum
concentration of approximately i06 M.
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INTRODUCTION
Sequence similarity has recently led to the assignment
of several small protein cytokines to a single family,
thought to participate in the response to injury [1-4].
These proteins make up single chains with molecular
masses in the 8,000-10,000 dalton range. A distinguish-
ing feature is the occurrence of four half-cystine residues
in the chain. When the sequences ofthe different proteins
are appropriately aligned, the proteins fall into two
subgroups according to the positions of the first two
haif-cystines (C-X-C or C-C), and all four half-cystine
residues are in register. The C-X-C subgroup includes
platelet factor-4 (PF-4), connective tissue activating
peptide-III (CTAP-III) , and NAP- 1 (also known as
interleukin-8). PF-4 and CTAP-III are platelet proteins,
which are released from a-granules when platelets are
activated. The biological role of PF-4 is not well estab-
lished. Reported activities include heparmn binding [5],
chemotactic attraction of neutrophils [6] , release of mast
cell granules [7], stimulation of neutrophil elastase [8],
and inhibition of collagenase [9] . CTAP-III is mitogenic
for fibroblasts. It also stimulates hyaluronic acid and
sulfated glycosaminoglycan synthesis, glucose transport,
and prostaglandin E2 release [10]. NAP- 1 was first
identified as a product of lipopolysaccharide (LPS)-
stimulated monocytes [1 1] . It is a chemoattractant for
neutrophils, and also stimulates the metabolic burst [1].
The latest addition to the C-X-C family is called NAP-2,
since, like NAP-i , it is a neutrophil activator and
attractant [12, 13]. It is a truncated form of CTAP-III,
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derived by cleavage of the first 15 N-terminal residues
[12,14,15].’
We had two objectives in the experiments described in
this communication. The first was to compare chemo-
tactic potency and efficacy of the above C-X-C proteins,
to establish a basis for evaluating their significance in
vivo. We also included C5a and the C-terminal dode-
capeptide of PF-4 [PF-4(59-70)] in this study. C5a is of
interest in relation to platelet activation, since CS-derived
chemotactic activity can be generated by platelet en-
zymes released at the site of tissue injury [16]. The
chemotactic potency and efficacy of PF-4(59-70) for
neutrophils was reported to be comparable to that of the
native molecule [17] . This finding may have relevance to
other C-X-C proteins, in light of the recent nuclear
magnetic resonance study of NAP- 1 , which suggests that
the receptor-binding portion of the molecule is a C-
terminal a helix [18]. The second objective, relating to
the structural similarity of NAP-i , NAP-2, and PF-4,
was to determine if these agonists interacted with the
same neutrophil receptor. In addition to determining how
much genetic information is devoted to formation of
distinct chemoattractant receptors on neutrophils, the
question has a new focus because of the possibility noted
above that the receptor-interacting portion of NAP- 1 and
PF-4 is the C-terminal a helix. Agonist binding was
evaluated by determining the capacity of unlabeled
ligands to inhibit binding of NAP- l-fluorescein isothio-
cyanate (FITC) to human neutrophils.
MATERIALS AND METHODS
Reagents
All protein solutions used in this study were distributed
in aliquots sufficient for single experiments, quick-frozen
in liquid nitrogen, and stored at -80#{176}C.Recombinant
human CSa was a gift from Henry Showell (Pfizer
Central Research , Groton, CT). Human NAP- 1 was
purified to homogeneity from culture fluid of LPS-
stimulated monocytes [19] . Recombinant NAP- 1 was
prepared by Dainippon (Osaka, Japan) [20]. Fluoresce-
mated NAP- 1 (NAP- l-FITC) was prepared as previously
described [2 1 ] . NAP-2 was purified to homogeneity (as
judged by silver-staining of SDS-PAGE gels and se-
quencing of the N-terminus) from platelet-contaminated
human monocytes [ 12] . CTAP-III and CTAP-III(des
1-13) were purified from outdated platelets as recently
described [14]. We used two preparations of PF-4
purified to homogeneity from human platelets, one from
‘CTAP-III(des 1-15) is CTAP-III without the first 15 N-terminal
residues. It is also called neutrophil attractantlactivation protein-2
(NAP-2). The former nomenclature is structural, the latter functional.
Both terms are useful, depending on the context. In this paper on
functional comparison with NAP- 1. we use the NAP-2 terminology.
D. Walz [22] and one from A. Walz [13]. The C-terminal
dodecapeptide of PF-4, PF-4(59-70), was a synthetic
product [7] . Horse type VI cytochrome-c was from
Sigma (St. Louis, MO).
Measurement of Chemotactic Responses
Neutrophils were obtained by dextran sedimentation of
heparinized venous blood from normal human subjects.
We added 7 ml of 5% dextran T-500 (Pharmacia-LKB) to
20 ml of human blood. After 40 mm, about 1 2 ml of
supernatant plasma was removed and centrifuged. Eryth-
rocytes in the neutrophil pellet were lysed by the addition
of4 ml of4#{176}C0.2% NaCI, followed immediately by 4 ml
of 1 .6% NaC1. After centrifugation, the pellet was
washed twice with cold Ca-Mg-free Hanks’ balanced salt
solution. The washed leukocytes, at least 90% neutro-
phils, were resuspended in 3 ml of Ca-Mg-free Hanks’
solution and stored in ice until use within 60-90 mm. As
soon as the neutrophils were isolated, serial dilutions of
agonists were made in 22#{176}CHanks’ solution, with or
without 50 jig/mi cytochrome-c. Bottom wells of multi-
well chemotaxis chambers [23] were filled in duplicate
with serial dilutions of attractants, and the chambers were
assembled, with 3-jim-pore-diameter polyvinylpyrroli-
done (PVP)-free polycarbonate membranes separating
upper cell wells from lower attractant wells. The cold
stock suspension of neutrophils was diluted at least
tenfold with 22#{176}CHanks’ solution, with or without SO
jig/mi cytochrome-c , to a final concentration of 7 X lO
neutrophils/mi. After addition of 50 jil/wehi, chambers
were incubated at 37#{176}Cin humidified air with 5% CO2 for
45 mm. The polycarbonate filter was then removed from
the chamber, nonmigrated cells were wiped off the upper
surface, and the filter was air-dried and stained with
Diff-Quik (American Scientific Products, McGaw Park,
IL).
Migrated neutrophils were examined microscopically
with a X 25 objective and an image analyzer. Three
randomly chosen fields per well were surveyed (a total of
0.48 mm2 of the 8 mm2 well area). The image analyzer
can count individual cells or determine the total area
occupied by stained cells. Since the former underesti-
mates cell number if migrated cells touch one another, we
determine migrated neutrophil area and converted to
number of neutrophils by dividing by an average area per
neutrophil.
Inhibition of NAP-1-FITC Binding by
Unlabeled Ligand
This was done exactly as described elsewhere [21].
Fixed concentrations of NAP- l-FITC were mixed with
increasing concentrations of unlabeled ligand and equil-
ibrated with neutrophils at 0#{176}C.The cells were then
washed and surveyed for bound fluorescence by flow
cytometry.
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RESULTS
Chemotactic Responses to the Different Ligands
A representative response of neutrophils to serial
fivefold dilutions of three different chemoattractants is
shown in Figure 1A. The chemotactic response as a
function of NAP-i or C5a rose to a peak and then
declined. This is typical of pure chemoattractants, pro-
vided that there is sufficient solubihity and amount of
attractant to cover the appropriate concentration range.
The number of neutrophils responding to NAP-2 was
comparable to the NAP-i or C5a response, but higher
concentrations ofNAP-2 were required. Figure lB shows
that PF-4(59-70) also caused neutrophil migration, but
only at concentrations that were about three orders of
magnitude higher than the NAP-i optimum.
Pooled data for this part of the study are shown in
Table i . The EC50 potency ratio column shows that CSa
and NAP- I are much more potent neutrophil attractants
than the other proteins listed. Although efficacy (peak
percentage migration) of NAP-2 was similar to that of
NAP- 1 , the EC50 was two orders of magnitude greater.
The limited supply ofCTAP-III(des 1-13) restricted us to
two chemotaxis experiments, which suggest potency and
efficacy comparable to that of NAP-2 (CTAP-III(des
1-15)]. The chemotactic response to CTAP-III (two
experiments) was undetectable or minimal, confirming
published results [13].
Among all agonists tested, PF-4(S9-70) caused the
highest neutrophil migration response, but the EC50
potency ratio was the lowest. Despite the high concen-
trations required, the response to PF-4(59-70) was pri-
manly chemotactic, not chemokinetic (Table 2). The first
column of Table 2 shows that PF-4(59-70) does not
induce chemokinesis, since there is only a minimal
increase in migration as a function of increasing concen-
trations of agonist in the cell suspension. The migration
response to PF-4(S9-70) in attractant wells only (Table 2,
first row) was inhibited when the positive gradient was
eliminated (Table 2, bottom row), which indicates that
the response is chemotactic. In contrast to the data for
PF-4(59-70), the responses to native PF-4 were low and
variable, with no significant effect on neutrophils from
six of nine subjects (Table 1). Lack of response to PF-4
occurred at concentrations as high as 1 .3 X i0 M,
which is tenfold higher than the EC50 for PF-4(59-70).
Inhibition of NAP-1-FITC Binding by
Unlabeled Agonists
Figure 2A illustrates the capacity of different members
of the C-X-C family to compete with NAP-i-FITC for
human neutrophil NAP-I binding sites. NAP-i was the
best competitor, followed by the truncated forms of
CTAP-III, and then by native CTAP-III. Figure 2B
shows another experiment, with NAP-i and NAP-2 at
comparable concentrations. Neither the C-terminal dode-
capeptide of PF-4 (Fig. 2B) nor native PF-4 (data not
shown) inhibited NAP-l-FITC binding. The results
indicate that NAP-2 interacts with the NAP- 1 receptor,
whereas PF-4(59-70) does not.
DISCUSSION
A major objective of this research was to compare
chemotactic activity of several members of the C-X-C
family of proteins under identical assay conditions.2
Assays were done in multiwehl chemotaxis chambers
with 3-jim-diameter pore size, 10-jim-thick PVP-free
polycarbonate membranes. This method lends itself to
quantitative evaluation, since many assay wells can be set
up in a short time, and migration data can be generated
by image analysis. The polycarbonate membrane should
be distinguished from the 150-jim-thick cellulosic filters
used by some investigators in classical studies on neu-
trophil chemotaxis [26]. We were concerned about the
possibility of loss of low concentrations of protein
agonists on the walls of dilution tube or chemotaxis well.
The total amount of protein lost from a solution is limited
by the adsorptive capacity of the container. Since the
percentage loss is negligible at protein concentrations of
50 jig/mi or higher [27], loss of agonist can be prevented
by dilution in a SOjig/mi solution of a nonreactive
protein. We found that addition of cytochrome-c to the
Hanks’ solution used for diluting attractants and prepar-
ing neutrophil suspensions did not affect neutrophil
random migration and sometimes improved attractant
2Methods for measurement of neutrophil chemotaxis differ greatly,
which probably accounts for disparate reports on activity of the same
agonist. Each method may have advantages. but, for comparison of
different agonists, one method should be selected. As noted. we use a
10-p.m-thick pohycarbonate membrane with 3 pm holes, through
which neutrophils can migrate toward the attractant. The number of
migrated neutrophils can be quantified, since they adhere to the
attractant side of the membrane. However, if we use a membrane
coated with PVP, or if bovine serum albumin (BSA) is added to the
medium, 20-50% ofthe migrated neutrophihs fall off into the attractant
well [24]. Since migrated neutrophils are variably distributed between
membrane and attractant well fluid in the presence of BSA, counts of
either membrane-adherent or well fluid neutrophils will underestimate
the total migrated number, and this will affect calculated efficacy as
well as the shape of the dose-response curve. When a I50-im-thick
cellulosic filter is used for chemotaxis assays, the response is
frequently quantified by the leading front method, which measures the
distance traveled by the two neutrophils that migrated the farthest into
the filter. By this method, for example. NAP-l activity was detected
at lO ‘#{176}M 1251. However. this figure cannot be related to our data in
Table 1 , since leading front data provide no information about the
concentration of agonist required for migration of the bulk of the
neutrophils or about chemotactic efficacy (percentage of input neutro-
phils migrating). In the study of Harvath et al. 1241. detectable
neutrophil migration occurred at I0 0 M fMLP, whereas peak
efficacy requires 10” M.
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Fig. 1 . A: Migration response of human neutrophils to NAP-i , NAP-2, and C5a. B: Response of
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TABLE 1. Chemotactic Efficacy and Potency of Attractants
Peak %
migration Molarity at peak EC50 Potency ratio’
C5a 33 ± Sb (6) 1 ± 0.3 X l0 9 ± 2 X l0 1,800
NAP-l 23 ± 4 (7) 6 ± 2 X 108 1 ± 0.4 X l08 1,600
rNAP-l 23 ± I (5) 4 ± 2 X 1O 4.2 ± 1 X l0 3,800
NAP-2 26 ± 3 (7) 5 ± 0 X 10 1.2 ± 0.2 X l0” 13
CTAP-III(des l_13)c 19 ± 3 (2) 5 ± 0 X l06 1.4 ± 0.6 X l06 11
PF-4 19 ± 3 (3)d 4 ± 1 X 106 1.3 ± 0.3 X 106 12
PF-4(59-70) 40 ± 3 (6) 1 ± 0 X iO 1.6 ± 0.5 X iO I
aReciprocal of EC5 agonist/EC50 PF4(59-70).
bSEM for indicated number of experiments (in parentheses) with different subjects.
CCTAPIII (not truncated) was tested twice. There was no response with one subject; the 8%
migration peak at 5 X 1 06 M with the other was not necessarily significant, since there was
polyethylene glycol in the CTAP-III, which causes neutrophil migration.
dAmong six other donors tested with PF-4, there was no response in four, neutrophil clumping in one,
and very low response without a dose-response trend in one. One of two lots of PF-4 (purified by A.
Walz or D. Walz) was used in these experiments. Each lot was represented among both responders
and nonresponders.
TABLE 2. Response to Comb inations of PF-4(59-70) in Cell and Attractan t Wells
LPF-4(59-70)l (M)
in cell well
LPF-4(59-70)l (M) in attractant well
0 106 5 X 106 2.5 ± l0 1.3 X l0
0 0.7’ 0.5 4.2 10.8 10.4
106 0.6 1.4 5.9 6.4 8.1
5 x l06 0.7 0.6 1.9 6.0 7.1
2.5 X l0 1.1 2.2 3.7 7.0 -
1.3 X l0 2.0 1.4 1.4 1.2 3.4
0 0.9 2.5 5.0 7.5 11.7
10.6 1.0 2.1 6.2 10.6 8.6
5 X l06 1.3 1.1 4.6 7.5 8.9
2.5 X iO 1.6 2.1 3.4 11.5 5.9
1.3 X l0 0.8 1.4 1.5 3.7 6.4
‘Migrated neutrophils per well X l0. Inputneutrophil number was 35,000. All cell suspensions and
attractants were in 50 g/ml cytochrome-c in Hanks’ balanced salt solution. Data are from
experiments with neutrophils from two different human subjects.
potency by one serial dilution step at low concentrations
of agonist. We avoided BSA, because of the variable
effects of this protein on random migration and chemo-
tactic responses.
Our results show that chemotactic potency and efficacy
of NAP-i and C5a for neutrophils are comparable. We
confirm a report by A. Walz et al. [13] that NAP-2 is a
neutrophil attractant, with efficacy comparable to that of
NAP- 1 . In contrast to that report, we find that NAP-2
potency is lower than that of NAP-i . Consistent with our
results is the fact that NAP-2 is not as effective as NAP-i
in competing with NAP-i-FITC for binding sites on
neutrophils (Fig. 2, Table 3). The chemotaxis assay used
by Walz et al. [13] differs from ours (BSA in the
medium, longer incubation, collection of migrated cells
that do not adhere to the membrane, and much higher
random migration). It is likely that the observed differ-
ences in NAP-2 potency relate to a methodological detail
of the chemotaxis assay , since the NAP-2 in both studies
was purified by A. Walz.
The C-terminal dodecapeptide of PF-4 also caused
neutrophil migration, although responses comparable in
magnitude to that of NAP- 1 or C5a required 1 ,000-fold
higher concentrations . Whereas NAP-i and NAP-2,
which have considerable sequence similarity, appear to
interact with the NAP- i neutrophil receptor, PF-4(59-70)
does not. The chemotactic activity of this C-terminal
portion of PF-4 is of great interest in light of the recent
nuclear magnetic resonance study [1 8] of NAP- 1 in
solution, suggesting that a C-terminal a helix, mounted
on a 3 sheet formed by residues 56-72, is the part of the
molecule that reacts with the receptor. However, PF-4
preparations from two different sources had minimal
chemotactic activity in our study. This confirms results
CTAP-III










Fig. 2. Inhibition of binding of NAP-i-FITC to human neutro-
phils by unlabeled ligands. A: CTAP-lII, CTAP-lll(des 1-13),
CTAP-Ill(des 1-15) [NAP-2], and NAP-i. B: PF-4(59-70), NAP-2,
NAP-i . The 4 PF-4 symbols after the break represent fivefold
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curves are the result of mixing unlabeled ligand with 2 x i0 M
NAP-i-FITC. Data are mean fluorescence channel number mi-
nus autofluorescence channel number, expressed as a per-
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TABLE 3. In hibition of NA P-i-FITC Binding b y Unlabeled Ligand
Percent
Ligand inhibitiona IC5o Potency ratio
NAP-I (4)” 90 ± 3 2 ± .6 X 10-8 10
NAP-2 (4) 69 ± 5 8 ± 3 X l0 3
CTAP-IIl(des 1-13) (1) 58 2 X l0 I
CTAP-III (2) 33 ± 5 -C
aMaximal inhibition observed with different concentrations ofunlabeled ligand mixed with 2 X l0
M NAP- I -FITC. IC50 is molarity of unlabeled higand required for 50% inhibition. Potency ratio for
ligand is 1C50 of CTAP-IIIdes( I - 1 3)/IC50 of ligand.
hNumbers of experiments are in parentheses.
CDid not reach 50% inhibition.
obtained by Walz et al. [13] with one ofthe preparations,
but does not agree with previous reports on the chemo-
tactic activity ofPF-4 for neutrophils in the 107-i05 M
range [6, 17]. Since the chemotactic activity of PF-
4(59-70) suggests that neutrophils may have a receptor
for this ligand, additional experiments with purified
native PF-4 are warranted.
In light of our comparative study, it is of interest to
speculate about the generation and role of chemoattrac-
tants in tissue injury. Stored proteins are released from
platelet a granules in the initial response and this can lead
to formation of two chemoattractants from protein pre-
cursors. Secreted platelet products can activate CS to
become a chemoattractant [16]. The mechanism is prob-
ably similar to the cleavage by trypsin of a C-terminal
peptide of the a chain of CS , which induces chemotactic
activity even though the split products remain attached to
one another via a disulfide bond [28] . Platelet CTAP-III
becomes the NAP-2 chemoattractant when a 15-residue
fragment is cleaved from the N-terminus. Porcine
elastase [ 14] and enzymes in human monocyte culture
fluid [ 15] are capable of this cleavage If neutrophil
elastase can also cleave CTAP-III, there is a potential for
positive feedback generation of NAP-2. It should also be
noted that serum concentrations of CTAP-III are in the
range 5-35 jig/mI, which suggests that there would be
considerable CTAP-III substrate available at local sites of
platelet aggregation. Thus the lower potency of NAP-2
relative to CSa or NAP-i may not be a biological
limitation. In summary, chemotactic attraction of neu-
trophils to sites of tissue injury could be mediated early
by enzymatic activation of two precursors, CS and
CTAP-III . The products-activated CS and NAP-2-
engage CSa and NAP- 1 receptors. Since NAP- 1 is not
preformed, it would appear later, after a stimulus such as
LPS or interleukin- 1 causes synthesis and secretion by
cells at the site of injury. The time from production
stimulus to secretion is short; NAP-i was detected in
human lung macrophage culture fluids as early as 6 hr
after stimulation by LPS [29].
ACKNOWLEDGMENTS
E.J.G. was supported in part by a research contract
from Stimmune Biotechnologies Division of Rainin In-
strument Co., Inc. D.A.W. was supported in part by
National Institutes of Health grant HL 27073.
REFERENCES
1 . Baggiolini. M. , WaIz. A. . and Kunkel, S.L. Neutrophil-acti-
vating peptide-l/interleukin 8, a novel cytokine that activates
neutrophils. J. Chin. Invest. 84.1045, 1989.
2. Leonard, E.J. , and Yoshimura. T. Human monocyte chemoat-
tractant protein-l (MCP-l ). Immunol. Today I 1 ,97, 1990.
3. Matsushima, K. , and Oppenheim. ii. Interleukin 8 and MCAF:
Novel inflammatory cytokines inducible by IL- I and TNF.
Cytokine 1,2, 1989.
4. Leonard, E.J. , and Yoshimura. T. Neutrophil attractantlactivation
protein-l [NAP-I (IL-8)l. Am. J. Respir. Cell Mol. Biol. 2.479,
1990.
5. Handin, RI. , and Cohen, Hi. Purification and binding properties
of human platelet factor four. J. Biol. Chem. 25 1 ,4273. 1976.
6. Deuel, T.F. . Senior, R.M. , Chang, D. , Griffin, G.L. . Heinrik-
son, R.L. , and Kaiser, E.T. Platelet factor 4 is chemotactic for
neutrophils and monocytes. Proc. Nath. Acad. Sci. USA 78.4584.
1981.
7. Brindley, L.L. , Sweet, J.M. , and Goetzl, E.J. Stimulation of
histamine release from human basophils by human platelet factor
4. J. Clin. Invest. 72.1218, 1983.
8. Lonky, S.A. , and Wohl, H. Stimulation of human leukocyte
elastase by platelet factor 4. Physiologic, morphologic and
biochemical effects on hamster lungs in vitro. J. Chin. Invest.
67,817, 1981.
9. Hiti-Harper, J. , Wohl, H. , and Harper, E. Platelet factor 4: an
inhibitor of collagenase. Science 199,991 , 1978.
10. Castor, C.W. Regulation of connective tissue metabolism. In
Arthritis and Allied Conditions. I lth ed. (McCarty, D.J. , Ed.).
Philadelphia: Lea & Febiger, p 242, 1988.
I I . Yoshimura, T. , Matsushima, K. , Oppenheim, J.J. , and Leonard,
E.J . Neutrophil chemotactic factor produced by hipopolysaccha-
ride (LPS) stimulated human blood mononuclear leukocytes. I.
Partial characterization and separation from interheukin-l (IL-h).
J. Immunoh. 139,788, 1987.
12. Walz, A. , and Baggiolini, M. A novel cleavage product of
3-thromboglobuhin formed in cultures of stimulated mononuclear
cells activates human neutrophils. Biochem. Biophys. Res. Com-
mun. 159,969. 1989.
Chemotactic Activity of NAP-i and Related Proteins 265
13. WaIz, A. , Dewald, B. . von Tscharner, V. . and Baggiohini. M.
Effects of the neutrophil-activating peptide NAP-2. platelet basic
protein, connective tissue-activating peptide III, and platelet
factor 4 on human neutrophils. J. Exp. Med. 170.1745, 1989.
14. Castor, C.W. , WaIz, D.A. , Ragsdale, C.G. , Hossler, PA.,
Smith, EM. . Bignall. MC. , Aaron, B.P. , and Mountjoy. K.
Connective tissue activation XXXIII. Biologically active cleavage
products of CTAP-III from human platelets. Biochem. Biophys.
Res. Commun. 163, 107 1 , 1989.
15. Walz, A. , and Baggiohini, M. Generation of the neturophil-
activating peptide NAP-2 from platelet basic protein or connective
tissue activating peptide III through monocyte proteases. J. Exp.
Med. 171,449, 1990.
16. Weksher, B.B. , and Coupal, CE. Platelet-dependent generation
of chemotactic activity in serum. J. Exp. Med. 137.1419. 1973.
17. Goldman. D.W. . Hannah, AL. , and Goetzh, E.J. Inhibition of
human neutrophil receptor-mediated uptake of N-formyh-met-
leu-phe by platelet factor 4(59-70). Immunology 54,163, 1985.
18. Chore. G.M., Appella, E. , Yamada, M. , Matsushima, K., and
Gronenborn, AM. The three-dimensional structure of interleu-
kin-8 in solution. Biochemistry 29,1689, 1990.
19. Yoshimura. T. . Robinson, E.A. , Appella, E. . Matsushima, K.,
Showalter, S.D. , Skeel, A. , and Leonard, E.J. Three forms of
monocyte-derived neutrophil chemotactic factor (MDNCF) dis-
tinguished by different lengths of the amino-terminal sequence.
Mol. Immunol. 26.87. 1989.
20. Furuta. R. , Yamagishi, J. , Hiotada, K. , Sakamoto, F. , Fukui, T.,
Matsui, Y., Sohmura, Y., Yamada, M., Yoshimura, T., Larsen,
C.G.. Oppenheim. J.J., and Matsushima, K. Production and
characterization of recombinant human neutrophil chemotactic
factor. J. Biochem. 106,436. 1989.
21. Leonard, E.J., Skeel, A., Yoshimura, T., Noer, K., Kutvirt, S.,
and van Epps, D. Leukocyte specificity and binding of human
neutrophil attractant/activation protein-I (NAP-l). J. Immunol.
144.1323, 1990.
22. Ciaglowski, RE. , Snow, J. , and Walz, D.A. Isolation and amino
acid sequence of bovine platelet factor 4. Arch. Biochem.
Biophys. 250,249, 1986.
23. Falk. W. , Goodwin, RH. , Jr. , and Leonard, E.J. A 48-well
microchemotaxis assembly for rapid and accurate measurement of
leukocyte migration. J. Immunol. Methods 33,239, 1980.
24. Harvath, L. , Falk, W. , and Leonard, E.J. Rapid quantitation of
neutrophil chemotaxis: Use of a polyvinylpyrrolidone-free poly-
carbonate membrane in a multiwell assembly. J. Immunol.
Methods 37,39, 1980.
25. Lindley, I. , Aschauer, H. , Seifert, J.-M. , Lam, C. , Brunowsky,
W. , Kownatzki, E. . Thelen, M. , Peveri, P. , Dewald, B. , von
Tscharner, V. , WaIz, A. , and Baggiolini, M. Synthesis and
expression in Escherichia coli of the gene encoding monocyte-
derived neutrophil-activating factor: biological equivalence be-
tween natural and recombinant neutrophil-activating factor. Proc.
Natl. Acad. Sci. USA 85,9199, 1988.
26. Wilkinson. P.C. Chemotaxis and Inflammation. Edinburgh:
Churchill Livingstone, p 33, 1974.
27. Askenase, P.W. . and Leonard, E.J. Solid phase radioimmunoas-
say of beta-h-C globulin. Immunochemistry 7,29, 1970.
28. Wetsel, R.A. , and Kolb, W.P. Complement-independent activa-
tion of the fifth component (CS) of human complement: Limited
trypsin digestion resulting in the expression ofbiohogic activity. J.
Immunol. 128,2209, 1982.
29. Rankin, iA. , Sylvester, I. , Smith, S. , Nolfo, R. , and Leonard,
E.J. Alveolar macrophages culture in vitro release LTB4 and
neutrophil attractantlactivation protein-l INAP]l (IL-8)j sequen-
tially in response to stimulation with LPS and zymosan. J. Clin.
Invest. 86,1556. 1990.
